Form 4: aTYR PHARMA General Counsel Reports RSU Vesting, Tax Sale

aTYR PHARMA's General Counsel, Nancy Denyes, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Nancy Denyes, General Counsel of aTYR PHARMA INC, reported changes in her beneficial ownership.
• On February 3, 2026, 2,687 shares of common stock were acquired upon the vesting of restricted stock units (RSUs).
• These RSUs were granted on February 3, 2022, and vest in four equal annual installments, fully vesting on February 3, 2026.
• On February 4, 2026, 1,118 shares of common stock were sold at a price of $0.9761 per share.
• This sale was conducted to satisfy tax withholding obligations related to the partial vesting of the RSUs.
• Following these transactions, Nancy Denyes beneficially owns 33,124 shares of aTYR PHARMA common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's a sale, it's for tax purposes following RSU vesting, indicating continued long-term equity alignment for the General Counsel.

Positives

• The acquisition of 2,687 shares by General Counsel Nancy Denyes through RSU vesting indicates continued equity ownership and alignment with shareholder interests.

Negatives

• The sale of 1,118 shares by General Counsel Nancy Denyes, even if for tax obligations, reduces her direct beneficial ownership.

Future Outlook

The remaining Restricted Stock Units (RSUs) are scheduled to fully vest on February 3, 2026. The RSUs are also subject to accelerated vesting upon termination without cause following a change of control of the Issuer.

Management Comments

• The sale was made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vesting and subsequent tax-related sales, are common across the biotechnology and pharmaceutical industries. These transactions typically reflect pre-planned equity compensation structures rather than discretionary investment decisions, and are generally not indicative of significant shifts in company outlook or performance.

Comparison to Industry Standards

• The structure of Restricted Stock Units (RSUs) vesting over several years is a standard equity compensation practice in the biotechnology sector, comparable to plans at companies like Amgen or Gilead Sciences, which use similar long-term incentive programs to retain key executives.
• The sale of shares to cover tax withholding obligations upon RSU vesting is a common and expected event for executives receiving equity compensation across all industries, aligning with practices observed at major corporations globally.

Stakeholder Impact

• Shareholders: Minor, routine insider activity. The General Counsel maintains significant equity ownership, aligning her interests with shareholders.
• Employees: Reflects standard equity compensation practices for executives.

Next Steps

• The remaining Restricted Stock Units (RSUs) are scheduled to fully vest on February 3, 2026.

Key Dates

Keywords

aTYR PHARMA, ATYR, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Nancy Denyes, General Counsel, Equity Compensation, Stock Sale